Idorsia (IDIA) Company presentation summary

Strategic highlights and value creation

• Two products, QUVIVIQ (daridorexant) and TRYVIO/JERAYGO (aprocitentan), are positioned for blockbuster potential, with QUVIVIQ becoming a global standard for insomnia and TRYVIO/JERAYGO as the first systemic hypertension therapy targeting the endothelin system.

• Multiple late-stage and first-in-class pipeline assets, including partnerships with Viatris for selatogrel and cenerimod, support long-term innovation and value creation.

• Completed debt restructuring in 2025, securing CHF 169M liquidity at year-end and enabling continued investment in growth and R&D.

• Focused on expanding QUVIVIQ globally, maximizing TRYVIO/JERAYGO value, and advancing R&D milestones in 2026.

Product performance and market expansion

• QUVIVIQ sales grew from CHF 31M in 2023 to CHF 134M in 2025, with 2026 guidance at CHF 200M; US and EU exclusivity extend to at least 2036 and 2037, respectively.

• QUVIVIQ demonstrated significant improvements in sleep parameters and daytime functioning, with a safety profile comparable to placebo.

• Rapid market share growth in Japan, Europe, and China, with strong early uptake and expansion into primary care and digital channels.

• TRYVIO/JERAYGO approved in major markets, uniquely positioned for resistant hypertension, and targeting a $5B peak sales opportunity.

Financial and operational performance

• Materially lowered operating expenses while increasing sales, resulting in improved non-GAAP operating results.

• Successful equity financing and asset-backed debt restructuring provided strong liquidity and financial flexibility.

• Capital allocation prioritizes high-impact assets, commercial partnerships, and ROI-driven investment in pipeline innovation.